HFK 2
Alternative Names: HFK-2; TL01 conjugated liposomeLatest Information Update: 28 Apr 2025
At a glance
- Originator HighField Biopharmaceuticals
- Class Antibodies; Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 Apr 2025 HighField Biopharmaceuticals files an IND application with the NMPA in China for Solid tumours
- 21 Apr 2025 HighField Biopharmaceuticals plans a phase I trial in Solid tumours (Combination therapy, Second-line therapy or greater) in China
- 25 Sep 2024 Preclinical trials in Cancer in China (unspecified route) (HighField Biopharmaceuticals pipeline, September 2024)